Toronto, Canada, Sept. 14, 2026 (GLOBE NEWSWIRE) -- GH Power Inc. ("GH Power" or the "Company") (NYSE:MTNB), a Canadian clean energy and critical materials technology company, today announced that it
BEDMINSTER, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the "Company") (NYSE:MTNB) announced today that on August 31, 2026, it received a notice (the "Notice") from the
GH Power Inc. ("GH Power"), a Canadian clean energy and critical materials technology company, today confirmed that the Government of Canada has selected TKMS, one of the world's leading naval shipbuilders
Following the transaction, the new public company will focus its efforts on the continued development and scale-up of GH Power’s technology platform, expanding project development activities in North America and
Will create publicly traded advanced clean energy company focused on modular carbon-free energy, green hydrogen, critical materials and industrial decarbonization Business Combination expected to provide public market
BEDMINSTER, N.J., June 26, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the "Company") (NYSE:MTNB) announced today that on June 24, 2026, it received a notice (the "Notice") from the NYSE
BEDMINSTER, N.J., April 03, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the "Company") (NYSE:MTNB) announced today that on April 2, 2026, it received a notice (the "Notice") from the NYSE American LLC
BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of
BEDMINSTER, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) (the "Company") today announced that the Company entered into a securities purchase agreement (the "Agreement") with a
BEDMINSTER, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of Evelyn D'An to its Board of Directors as an independent director and Chair of the
NEW YORK, Jan. 24, 2025 /PRNewswire/ - 111 Equity Group, LLC ("111 Equity") and its principal filed a Schedule 13D with the Securities and Exchange Commission ("SEC") to disclose that 111 Equity and its
BEDMINSTER, N.J. , Jan. 10, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) announces that on January 6, 2025, it received a NYSE American LLC notice indicating that the Company has fallen below
BEDMINSTER, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) announces that negotiations under the previously disclosed non-binding term sheet regarding global rights to MAT2203, its
Signs non-binding term sheet granting global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections 31 patients have enrolled in the MAT2203
BEDMINSTER, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal
